Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain.

The estrogen receptor (ER) is a strong hormone-inducible transcription factor that regulates the expression of many genes. It was shown for the human progesterone receptor that the binding of hormone causes distinct conformational changes in the ligand binding domain (LBD) and that these changes in LBD conformation are crucial for events after DNA binding. We now show that conformational changes in the LBD of the human ER are a prerequisite for trans-activation. Under the appropriate conditions ER binds to its response element and activates transcription only in the presence of ligand. Binding of the ligand causes changes in the conformation of the LBD. Antihormones induce distinct conformational changes, the differences between the conformations lying in the carboxy-terminal end of the receptor. Changing the experimental conditions results in a receptor that can bind to DNA and activate transcription in a ligand-independent manner. Under these conditions the LBD has a transcriptionally active conformation in the absence of ligand. Taken together, our data indicate that the conformational change induced by ligand is required for converting a receptor to the transcriptionally active form.

[1]  Richard Treisman,et al.  Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element , 1988, Cell.

[2]  E. Baulieu,et al.  Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones , 1984, Nature.

[3]  B. Katzenellenbogen,et al.  Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. , 1992, The Journal of biological chemistry.

[4]  W. Pratt,et al.  The 56-59-kilodalton protein identified in untransformed steroid receptor complexes is a unique protein that exists in cytosol in a complex with both the 70- and 90-kilodalton heat shock proteins. , 1990, Biochemistry.

[5]  M. Brown-Luedi,et al.  Sequence homologies in the region preceding the transcription initiation site of the liver estrogen-responsive vitellogenin and apo-VLDLII genes. , 1984, Nucleic acids research.

[6]  K. Yamamoto,et al.  A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptor , 1988, Cell.

[7]  B. O’Malley,et al.  Recombinant human glucocorticoid receptor induces transcription of hormone response genes in vitro. , 1990, The Journal of biological chemistry.

[8]  B. O’Malley,et al.  The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex , 1990, Cell.

[9]  B. O’Malley,et al.  Hormone activation of baculovirus expressed progesterone receptors. , 1992, The Journal of biological chemistry.

[10]  S. Fawell,et al.  Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Chambon,et al.  The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. , 1989, The EMBO journal.

[12]  J. Katzenellenbogen,et al.  Desmethylnafoxidine aziridine: an electrophilic affinity label for the estrogen receptor with high efficiency and selectivity. , 1987, Journal of steroid biochemistry.

[13]  K. Korach,et al.  Uterine estrogen receptor-DNA complexes: effects of different ERE sequences, ligands, and receptor forms. , 1991, Molecular endocrinology.

[14]  K. Korach,et al.  The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. , 1991, Endocrinology.

[15]  E. Baulieu.  Steroid hormone antagonists at the receptor level: A role for the heat‐shock protein MW 90,000 (hsp 90) , 1987, Journal of cellular biochemistry.

[16]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[17]  D. Edwards,et al.  Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.

[18]  B. O’Malley,et al.  Identification of a functional intermediate in receptor activation in progesterone-dependent cell-free transcription , 1990, Nature.

[19]  V. Jordan,et al.  Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.

[20]  B. O’Malley,et al.  Specific binding of estrogen receptor to the estrogen response element , 1989, Molecular and cellular biology.

[21]  B. O’Malley,et al.  Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Jan Wijnholds,et al.  Oestrogen facilitates the binding of ubiquitous and liver-enriched nuclear proteins to the apoVLDL II promoter in vivo , 1991, Nucleic Acids Res..

[23]  P. Sharp,et al.  Human estrogen receptor forms multiple protein-DNA complexes. , 1990, The Journal of biological chemistry.

[24]  G. Greene,et al.  Immunochemical studies of estrogen receptors. , 1984, Journal of steroid biochemistry.

[25]  B. O’Malley,et al.  Mechanism of estrogen receptor-dependent transcription in a cell-free system , 1990, Molecular and cellular biology.